These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65 related articles for article (PubMed ID: 31507079)
1. Bayesian single-to-double arm transition design using both short-term and long-term endpoints. Xu T; Shi H; Lin R Pharm Stat; 2023; 22(4):588-604. PubMed ID: 36755420 [TBL] [Abstract][Full Text] [Related]
2. Performance of multinomial designs in comparison with response-based designs in non-randomized phase II trials of targeted cancer agents. Jamal R; Goodwin RA; Tu D; Walsh W; Lacombe D; Eisenhauer EA Ann Oncol; 2013 Jul; 24(7):1936-1942. PubMed ID: 23553058 [TBL] [Abstract][Full Text] [Related]
3. An overview of the adaptive designs accelerating promising trials into treatments (ADAPT-IT) project. Meurer WJ; Lewis RJ; Tagle D; Fetters MD; Legocki L; Berry S; Connor J; Durkalski V; Elm J; Zhao W; Frederiksen S; Silbergleit R; Palesch Y; Berry DA; Barsan WG Ann Emerg Med; 2012 Oct; 60(4):451-7. PubMed ID: 22424650 [TBL] [Abstract][Full Text] [Related]
4. Early stopping in clinical PET studies: How to reduce expense and exposure. Svensson JE; Schain M; Knudsen GM; Ogden RT; Plavén-Sigray P J Cereb Blood Flow Metab; 2021 Nov; 41(11):2805-2819. PubMed ID: 34018825 [TBL] [Abstract][Full Text] [Related]
5. Estimation of the odds ratio from multi-stage randomized trials. Cao S; Jung SH Pharm Stat; 2024 Mar; ():. PubMed ID: 38462496 [TBL] [Abstract][Full Text] [Related]
6. Using an early outcome as the sole source of information of interim decisions regarding treatment effect on a long-term endpoint: The non-Gaussian case. Garcia Barrado L; Burzykowski T Pharm Stat; 2024 Jun; ():. PubMed ID: 38837876 [TBL] [Abstract][Full Text] [Related]
7. A two-stage design for phase II trials with time-to-event endpoint using restricted follow-up. Belin L; De Rycke Y; Broët P Contemp Clin Trials Commun; 2017 Dec; 8():127-134. PubMed ID: 29696201 [TBL] [Abstract][Full Text] [Related]
8. Stopping Trials Early Due to Harm. Cook T; Buhule OD NEJM Evid; 2022 May; 1(5):EVIDctw2100026. PubMed ID: 38319224 [TBL] [Abstract][Full Text] [Related]
10. Progression-Free Survival Analysis With a Graphical Estimand Approach in the Phase 2 SAMCO-PRODIGE 54 Trial-Reply. Boussari O; Taïeb J JAMA Oncol; 2024 Apr; 10(4):540-541. PubMed ID: 38421669 [No Abstract] [Full Text] [Related]
11. Progression-Free Survival Analysis With a Graphical Estimand Approach in the Phase 2 SAMCO-PRODIGE 54 Trial. Tai YC; Wang W; Wells MT JAMA Oncol; 2024 Apr; 10(4):539-540. PubMed ID: 38421658 [No Abstract] [Full Text] [Related]
12. Using short-term endpoints to improve interim decision making and trial duration in two-stage phase II trials with nested binary endpoints. Zocholl D; Kunz CU; Rauch G Stat Methods Med Res; 2023 Sep; 32(9):1749-1765. PubMed ID: 37489267 [TBL] [Abstract][Full Text] [Related]
13. A two-stage phase II clinical trial design with nested criteria for early stopping and efficacy. DeVeaux M; Kane M; Wei W; Zelterman D Pharm Stat; 2019 Nov; 18(6):700-713. PubMed ID: 31507079 [TBL] [Abstract][Full Text] [Related]
14. Two-stage phase II oncology designs using short-term endpoints for early stopping. Kunz CU; Wason JM; Kieser M Stat Methods Med Res; 2017 Aug; 26(4):1671-1683. PubMed ID: 26037529 [TBL] [Abstract][Full Text] [Related]
15. Optimal and minimax three-stage designs for phase II oncology clinical trials. Chen K; Shan M Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337 [TBL] [Abstract][Full Text] [Related]
16. A flexible multi-stage design for phase II oncology trials. Tan MT; Xiong X Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328 [TBL] [Abstract][Full Text] [Related]